opportunistic infections Flashcards

1
Q

how are viruses classified

A

Baltimore classification
(by their replicative life cycle)

all produce positive sense mRNA -> generate proteins for their replication

nature of genomes mean different classes achieve this through different mechanisms -> implications of life cycle, dx and rx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

definition of opportunistic infection

A

An infection caused by an organism that does not normally cause disease

…Or symptomatology may be altered in the immunocompromised compared to immunocompetent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are endogenous opportunistic infections

A

Latent viruses that reactivate in the absence of a normal immune system
Acquired in the past prior to immune suppression – eg Varicella Zoster (VZV) and can get disemminated herpes zoster

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are exogenous opportunistic infections

A

acquired from the environment
Increased severity in the immunocompromised
– eg influenza, SARS-CoV-2.. Or even primary acquisition of VZV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

AIDs defining illness

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do we diagnose viruses

A

indirect detection
* see if ever had infection
* response of immune system to virus

direct detection
* currentlt have infection
* viral proteins - lateral flow/ag test
* viral genetic material
* PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

summarise indirect detection of virus using serology

A

measure levels of Ab in serum
IgM - active or resolving infection
IgG - indicates past infection >6wks ago

Ab levels are reduced in immunocomp

serological course may differ wih different virus eg hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

hepatitis A serology

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

hepatitis B serology

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PCR to detect virus

A

detect viral genome via amplification
sensitive and specific
viral load can be used to monitor infection
can remain +ve after infection has resolved.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how are viruses diagnosed in the immunocompromised

A

cant use serology - no immune system

screen for viral infections before give immunosuppression - identify infections that might reactivate, guide antiviral prophylaxis

**monitor with PCR **- means can see viral reactivation promptly -> Rx, detect infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A 51-year-old with a recent HSCT is unwell. Which is the most appropriate test?
ALT = 800 IU/mL

EBV IgG/IgM
HBV sAb
Parvovirus PCR
HEV PCR
CMV IgG/IgM

A

HEV PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

scale of immunosuppression and how it relates to risk of getting opportunistic viral infections

A

As go up list – immunosuppression increases – allogenic gives highest risk of opportunistic viral infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

summarise immunosuppression for transplant

A

In Hematopoietic stem-cell transplantation: conditioning regimen, eradicating pre-exisiting disease. Then ongoing immunosuppression to prevent graft versus host.

Solid organ: induction to prevent T cell activation and maintenance therapy to prevent rejection

haematopoietic: Conditioning – wipe out the disease – when conditioned – do the transplant – then wait while ait for transplant to take - neutrophils start to go up – need immunosuppression to prevent graft vs host disease.Can stop immunosuppression

In solid organ – not completely irradiating body but will be on lifelong immunosuppression. Trying to prevent T cell activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

sources of viral infection in transplant recipients

A

virus from graft - eg HBV (serostatus, risk assessment)
virus from host - eg HSV (serostatus, monitoring PCR, prophylaxis, pre-emptive therapy)
novel infection from infected individual eg VZV (isolation-barrier nursing, post exposure prophylaxsis, vaccinating contacts, control of diet)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

chronology of HSCT infections

A

day 0 is day of transplant - wait 30 days for neutrophils to start recoving
so in 1st 30 days - most worried about bacterial/fungal
then more concerned of viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

chronology of solid organ transplant infections

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

things screen for when immunosuppressed become unwell

A

Screen and molecular test according to symptoms
Screen for specific infections knowing that they are immunocompromised
Blood – PCR
Biopsy of gut/PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

considerations when using anti-virals in people who are immunosuppressed

A

pre-emptive rx
prophylaxis
increased doses
longer duration
combination therapy
increased levels of antiviral resistance
increased toxicity of antivirals - because have to give more for longer

20
Q

how are viral infections different in the immunocompromised

A

present differently
disseminated - multiple systems
different organs
more severe
oncogenic
lack of immune mediated cells

21
Q

difference between HSV in immunocompetent and immunocompromised

A

increased frequency
increased severity/risk of dissemination
more organs involved - pneumonitis, eosophagitis, hepatitis
increased risk of acyclovir resistance

HSV L = immunocompetent R = oesophagitis
22
Q

mx of HSV in immunocompromised

A

HIV - start antiretroviral therapy – as soon as get CD count up – they will stop getting viral infetcions

Prophylaxis:
* Test IgG before give transplant
If they have it – day 5x day acyclovir (until 1mo after bone marrow, 3-6mo after solid organ)

23
Q

varicella in immunosuppressed

A

chicken pox:
* pneumonitis
* encephalitis
* hepatitis
* purpura fulminans in neonate

shingles:
* multi-dermatomal/disseminated
* often late - presenting immunosuppresion

Desemminated varicella R - Purpura fulminans in neonate
24
Q

prevention of varicella in immunocompromised

A

Prophylaxis (prolonged if post-bone marrow) – acyclovir/valicyclovir – if bone marrow transplant >1yr

PEP (post exposure prophylaxis) – incubation can be 20(?) days – gave give IVIG within 10 days of contact

Vaccination

25
Q

treatment of varicella in immunocompromised

A

Varicella
Anti-viral (acyclovir/valicyclovir) for 7-10 days
IV until no new lesions; PO until all crusted

Zoster
Anti-viral (IV if disseminated) + analgesia
If Ramsay-Hunt: add steroids
If HZO: add topical steroids

Bells palsy or ophthalmic we add sterods to redcue inflammation

26
Q

A patient who received a stem cell transplant 2 weeks ago presents with mouth ulcers.
Which of the following viruses would you test for on the mouth swab?

A. Enterovirus PCR
B. Adenovirus PCR
C. HSV PCR
D. HHV6 PCR
E. HHV8 PCR

A

HSV PCR

27
Q

what is EBV and post-transplant lymphoprolfierative disease

A

Latently infected B cells – polyclonal activation
Predisposes to lymphoma
Occurs in solid organ or allogenic haematopoietic cell transplants
Related to the level of immunosuppression
Suspicion on rising EBV viral load (> 105 c/ml) and CT scan
Confirmation with biopsy of lymph nodes

28
Q

issues with EBV and immunosuppression

A

Onchogenesis
* B cell latency, high turn-over
* T-cells monitor/control this

B-cell lymphomas
PTLD (post-transplant lympho-proliferative disorder

29
Q

Mx of EBV in immunosuppressed

A

Monitor EBV levels (proactive monitoring) - reg PCR once or twice wk in stem cell transplant pts

Ix for lymphoma as needed

Rx: ?Rituximab – monoclonal Ab, small studies have shown benefits
Rx: reduce immunosuppression – need to decide whether infection of not being immunosuppressed is worse

30
Q

issues with CMV in immunosuppressed

A

HIV/AIDS: CD4 less than 50
* Ocular (retinitis)
* Polyradiculopathy
* Pneumonitis
* GI tract

SOT (solid organ transplant)
* Allograft disease
* GI tract (i.e. renal)

Gastroenteritis and severe diarrhoea can be a big issue – hard to know if graft vs host or CMV
31
Q

mx of cytomegalovirus in

A

Prophylaxis (i.e. lung transplant)

May need to do bronchiolar lavarge

Pre-emptive treatment (i.e. renal transplant / HSCT)

Treat if disease (HIV/AIDS)

Rx: Ganciclovir / Valganciclovir
Rx: Reduce immunosuppression

32
Q

difference between CMV in transplant between SOT and BMT

A

SOT: CMV remains latent in dendritic cells so if some of these are transplanted with organ -> very sick because dont have immune system to fight it

Likewise if a bmt is received from a donor who has never seen CMV before and the reciepent reactivates the latent CMV -> greater morbidity and mortality – donor immune system is naive to CMV and finds it hard to clear

33
Q

how do we prevent CMV in transplant patients

A

BMT patients we monitor and if the virus goes above a certain level we treat

Solid organ prophylaxis

34
Q

CMV treatment in transplant patients

A

Ganciclovir (IV): bone marrow suppression
Valganciclovir: oral and less toxic
Foscarnet (IV) (nephrotoxicity)
Cidofovir (nephrotoxicity)
Can give IVIg (with another drug ie antiviral for pneumonitis)

CMV treatment is fairly toxic and resistance is not uncommon

35
Q

summarise John Cunningham virus

A

polyomavirus
think get in childhood
no treatment
progressive leukoencephalopathy (PML)

effective antiretroviral therapy -> reduced PML in HIV +ve

also see PML when immunocomp due to:
* humanised monoclonal antibodies
* Natalizumab (for treatment of multiple sclerosis) so don’t continue them on the drug for >2yrs

36
Q

what is progressive multifocal leukoencephalopathy

A

Demyelination of white cells -> neurological deficits

Cognitive disturbance, personality change, motor deficits other focal neurological signs

dx: MRI and PCR on CSF

37
Q

what is BK virus

A

polyomavirus
double stranded DNA
resides in kidney
may reactivate in immunosuppressed ->
* haemorrhagic cystitis in BMT pts (catheter fills with blood)
* nephropathy in renal transplants

Rx:cidifovir which is nephrotic itself, so often the level of immunspression is reduced

38
Q

resp viruses in the immunocompromised

A

increased risk of complications eg pneumonitis esp with:

Influenza A and B
Parainfluenza 1, 2, 3 and 4
Respiratory Syncytial Virus (RSV)
Adenovirus
SARS-CoV-2

39
Q

mx of influenza A and B in immunocompromised

A

Oseltamivir (oral drug) for 5 days

If resistance/severe/immunosuppressed →zanamivir (inhalation or IV)

40
Q

mx of covid in immunocompromised

A

Sotrovimab or Casirivimab/imdevimab
Discuss with infection/virology team

41
Q

compare the different hepatitis biruses in immunocompromised

A

Hep A: more severe, vaccinate

Hep B: re-activation, vaccinate/prophylaxis

Hep C: ?increased fibrosis, Rx direct-acting antiviral

Hep E: chronic infection, reduce immunosuppression

42
Q

summarise Hep B in the immunocompromised

A

either:
* carriers have flare
* past infection can reactivate - RFs are: cell depleting therapies (i.e Rituximab), IL-6 inhibitors - tocilizumab

43
Q

prevention of hep B in immunocompromised

A

Nucleoside (lamivudine) nucleotide (tenofovir, entecavir)
Prophylaxis

44
Q

serology of hep B

A

The hepatitis B envelope antigen(HBeAg) is found between the core and lipid envelope within HBV and is present inbothacuteandchronic infection.
* indicatesactive viral replication-> higher risk oftransmissibility.
* used to distinguish activeandinactive chronic infection.

HBeAg seroconversionis the development ofantibodies against HBeAg(anti-HBe);
it marks a transitionfromactive diseaseto aninactive ‘carrier’ state.

Anti-HBe remains in serum for life and indicates acquired, natural immunity (i.e. immunity from a previous infection only)

45
Q

what is a possible case of monkeypox

A
46
Q

Mx of monkey pox

A

prophylaxis - small pox vaccine
isolation
isolation
analgesia
tecovirimat if very severe (eg encephalitis)
screen for other STIs
consider psychosocial impact
inform UKSHA